Amgen Inc (AMGN) 139.27 $AMGN
Final Glance: Biotechnology companies
AP - Mon Sep 08, 5:38PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Zenith Epigenetics Strengthens its Management Team with Key Appointments
PR Newswire - Mon Sep 08, 4:34PM CDT
Zenith Epigenetics Corp. ("Zenith" or the "Company"
today announced that it has appointed Joy Zhu, MD, PhD, as Chief Medical Officer, Sanjay Lakhotia, PhD, as Chief Business Officer, and Michael Yakes, PhD, as Vice President Drug Discovery and Exploratory Development.
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative
Business Wire - Mon Sep 08, 2:13PM CDT
Fitch Ratings has affirmed the ratings for Amgen Inc. (Amgen) including Amgen's 'BBB'/'F2' Issuer Default Rating (IDR). The Rating Outlook remains Negative. A full list of rating actions follows at the end of this press release.
Midday Glance: Biotechnology companies
AP - Mon Sep 08, 1:11PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Early Glance: Biotechnology companies
AP - Mon Sep 08, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals
PR Newswire - Mon Sep 08, 9:00AM CDT
Decision Resources Group finds that the market for psoriatic arthritis (PsA) therapies will grow nearly 66 percent, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to 2023 forecast period. In 2013, five marketed TNF-alpha inhibitors dominated sales in the PsA market with over 90 percent of the $2.3 billion major-market total; adalimumab (AbbVie/Eisai's Humira) was the overall sales leader. Over the next decade, TNF-alpha inhibitors will retain their sales-leading position, but recently launched treatments ustekinumab (Janssen's Stelara) and apremilast (Celgene's Otezla), together with noval therapies--which include the anti-interleukin-17 monoclonal antibodies secukinumab (Novartis), ixekizumab (Eli Lilly), and brodalumab (Amgen/AstraZeneca/Kyowa Hakko Kirin) and the Janus-kinase inhibitor tofacitnib (Pfizer's Xeljanz)--will account for approximately 21 percent of 2023 PsA sales combined in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
3 Reasons Sanofi's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 6:30AM CDT
Like almost all Big Pharmas, French biopharma Sanofi has had a number of key drugs lose patent protection over the last few years, resulting in a massive drop in earnings and revenue. Consequently, its shares have under-performed both the broader...
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label
at The Street - Mon Sep 08, 6:00AM CDT
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
Amgen To Present At The Morgan Stanley Global Healthcare Conference
PR Newswire - Fri Sep 05, 3:04PM CDT
Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014, at the Grand Hyatt New York in New York City, beginning at 9:10 a.m. ET. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:00PM CDT
Earlier this week, Amgen Inc. (AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its PCSK9 inhibitor, evolocumab (AMG 145) for the treatment of high cholesterol.
Cleveland Clinic's 2014 Medical Innovation Summit Examines Cancer Treatment And Personalized Medicine
PR Newswire - Thu Sep 04, 10:20AM CDT
Cleveland Clinic's 12th Annual Medical Innovation Summit will bring together more than 1,500 executives, investors, entrepreneurs and clinicians Oct. 26 to 29, 2014, in downtown Cleveland to examine the latest innovations in cancer treatment and personalized medicine.
The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and Aegerion
PR Newswire - Thu Sep 04, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the United Therapeutics (Nasdaq:UTHR-Free Report), Repros Therapeutics (Nasdaq:RPRX-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report) and Aegerion (Nasdaq:AEGR-Free Report).
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
Final Glance: Biotechnology companies
AP - Mon Sep 08, 5:38PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Zenith Epigenetics Strengthens its Management Team with Key Appointments
PR Newswire - Mon Sep 08, 4:34PM CDT
Zenith Epigenetics Corp. ("Zenith" or the "Company"
today announced that it has appointed Joy Zhu, MD, PhD, as Chief Medical Officer, Sanjay Lakhotia, PhD, as Chief Business Officer, and Michael Yakes, PhD, as Vice President Drug Discovery and Exploratory Development. Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remains Negative
Business Wire - Mon Sep 08, 2:13PM CDT
Fitch Ratings has affirmed the ratings for Amgen Inc. (Amgen) including Amgen's 'BBB'/'F2' Issuer Default Rating (IDR). The Rating Outlook remains Negative. A full list of rating actions follows at the end of this press release.
Midday Glance: Biotechnology companies
AP - Mon Sep 08, 1:11PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Early Glance: Biotechnology companies
AP - Mon Sep 08, 9:34AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals
PR Newswire - Mon Sep 08, 9:00AM CDT
Decision Resources Group finds that the market for psoriatic arthritis (PsA) therapies will grow nearly 66 percent, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to 2023 forecast period. In 2013, five marketed TNF-alpha inhibitors dominated sales in the PsA market with over 90 percent of the $2.3 billion major-market total; adalimumab (AbbVie/Eisai's Humira) was the overall sales leader. Over the next decade, TNF-alpha inhibitors will retain their sales-leading position, but recently launched treatments ustekinumab (Janssen's Stelara) and apremilast (Celgene's Otezla), together with noval therapies--which include the anti-interleukin-17 monoclonal antibodies secukinumab (Novartis), ixekizumab (Eli Lilly), and brodalumab (Amgen/AstraZeneca/Kyowa Hakko Kirin) and the Janus-kinase inhibitor tofacitnib (Pfizer's Xeljanz)--will account for approximately 21 percent of 2023 PsA sales combined in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
3 Reasons Sanofi's Stock Could Fall
George Budwell, The Motley Fool - Motley Fool - Mon Sep 08, 6:30AM CDT
Like almost all Big Pharmas, French biopharma Sanofi has had a number of key drugs lose patent protection over the last few years, resulting in a massive drop in earnings and revenue. Consequently, its shares have under-performed both the broader...
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label
at The Street - Mon Sep 08, 6:00AM CDT
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.
Amgen To Present At The Morgan Stanley Global Healthcare Conference
PR Newswire - Fri Sep 05, 3:04PM CDT
Amgen (NASDAQ:AMGN) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 10, 2014, at the Grand Hyatt New York in New York City, beginning at 9:10 a.m. ET. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck
PR Newswire - Fri Sep 05, 8:00AM CDT
Today, Analysts Review released its research reports regarding Novartis AG (NYSE: NVS), InterMune Inc. (NASDAQ: ITMN), Johnson & Johnson (NYSE: JNJ), Amgen Inc. (NASDAQ: AMGN) and Merck & Co., Inc. (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6244-100free.
Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:00PM CDT
Earlier this week, Amgen Inc. (AMGN) announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its PCSK9 inhibitor, evolocumab (AMG 145) for the treatment of high cholesterol.
Cleveland Clinic's 2014 Medical Innovation Summit Examines Cancer Treatment And Personalized Medicine
PR Newswire - Thu Sep 04, 10:20AM CDT
Cleveland Clinic's 12th Annual Medical Innovation Summit will bring together more than 1,500 executives, investors, entrepreneurs and clinicians Oct. 26 to 29, 2014, in downtown Cleveland to examine the latest innovations in cancer treatment and personalized medicine.
The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and Aegerion
PR Newswire - Thu Sep 04, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the United Therapeutics (Nasdaq:UTHR-Free Report), Repros Therapeutics (Nasdaq:RPRX-Free Report), Amgen (Nasdaq:AMGN-Free Report), Regeneron (Nasdaq:REGN-Free Report) and Aegerion (Nasdaq:AEGR-Free Report).
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen
PR Newswire - Thu Sep 04, 7:55AM CDT
On Wednesday, September 03, 2014, the NASDAQ Composite ended at 4,572.57, down 0.56%, the Dow Jones Industrial Average finished the day 0.06% higher at 17,078.28, and the S&P 500 closed at 2,000.72, down 0.08%. During the trading session, six out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 740.75, up 0.41%, with the index advancing 6.93% in the previous three months. Investor-Edge has initiated coverage on the following equities: ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Arrowhead Research Corporation (NASDAQ: ARWR), Celgene Corporation (NASDAQ: CELG), and Amgen Inc. (NASDAQ: AMGN). Free research on these five companies can be accessed at:
